0
Obstructive Lung Diseases |

Hemidiaphragm Paresis and Granulomatous Pneumonitis Associated With Adalimumab

Tarek Abdallah, MD; Dany Elsayegh, MD; Mokhtar Abdallah, MD; Chadi Saifan, MD; Michel Chalhoub, MD; Louis Sasso, MD
Author and Funding Information

SIUH, Staten Island, NY


Chest. 2013;144(4_MeetingAbstracts):674A. doi:10.1378/chest.1703150
Text Size: A A A
Published online

Abstract

SESSION TITLE: Interstitial Lung Disease Case Report Posters II

SESSION TYPE: Affiliate Case Report Poster

PRESENTED ON: Tuesday, October 29, 2013 at 01:30 PM - 02:30 PM

INTRODUCTION: Adalimumab is a fully human monoclonal anti-TNF-alpha antibody. Reported adverse effects have highlighted a number of safety concerns associated with its prolonged use.

CASE PRESENTATION: A 57 year old male, non smoker, presents for worsening dyspnea, orthopnea, cough and wheezing. He failed treatment with inhaled corticosteroids and albuterol for two months. He had inactive Crohn’s disease for six years and rheumatoid arthritis diagnosed eight months earlier and was started on Adalimumab injections 40 mg once weekly. His respiratory symptoms appeared on his fourth month of therapy, he attributed them to the medication and discontinued the injections. His physical exam was unremarkable and had normal oxygen saturation. Chest radiograph showed a new elevated right hemidiaphragm.PFT’s showed new moderate restrictive pattern with 50% reduction of DLCO as compared to normal PFT’s two months ago. A HRCT chest showed bilateral lower lobe non-specific interstitial disease (figure 1). Chest fluoroscopy showed right hemidiaphragm paresis. Open lung biopsy showed subacute granulomatous pneumonitis with variable airspace organization compatible with idiosyncratic reaction to medication. (figure 2)

DISCUSSION: A potential association between TNF-alpha inhibitors and demyelinating disease has been suggested but not proven. A 2001 review of cases of demyelinating disease in the FDA database revealed 19 cases associated with the use anti TNF alpha inhibitors. [1].Demyelination clinically manifest as confusion, ataxia, and paresthesia.Neurologic findings included facial nerve palsy, optic neuritis, hemiparesis, transverse myelitis, and Guillain-Barré syndrome.There was a clear temporal relationship between nerurolgic events and anti-TNF-alpha therapy, and all symptoms partially or completely resolved upon discontinuation of the medication. Phrenic neuropathy following adalimumab therapy was reported.[2]Phrenic neuropathy association with Crohn’s disease or rheumatoid arthritis was not reported. Granulomatous pneumonitis was associated with TNF alpha inhibitor therapy.[3] The onset of respiratory symptoms only after his fourth months of therapy with Adalimumab raises a high suspicion that the abnormal findings are adverse effects of Adalimumab that clinicians must be aware of.

CONCLUSIONS: In summary, the onset of respiratory symptoms in patients on Adalimumab should be an alarming sign.

Reference #1: Mohan, N., et al., Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum, 2001. 44(12): p. 2862-9

Reference #2: Alexopoulou, A., et al., Acute bilateral phrenic neuropathy following treatment with adalimumab. Clin Rheumatol, 2009. 28(11): p. 1337-40

Reference #3: Khasnis, A.A. and L.H. Calabrese, Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum, 2010. 40(2): p. 147-63.

DISCLOSURE: The following authors have nothing to disclose: Tarek Abdallah, Dany Elsayegh, Mokhtar Abdallah, Chadi Saifan, Michel Chalhoub, Louis Sasso

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543